Related Experiment Video

Updated: Jun 5, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Antibody-based fusion proteins to target death receptors in cancer

Marco de Bruyn1, Edwin Bremer, Wijnand Helfrich

  • 1Department of Surgery, Surgical Research Laboratories, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.

Cancer Letters
|January 11, 2011
PubMed

Insights

Antibody fusion proteins targeting cancer cells with death ligands are inactive until binding. These scFv:sTRAIL and scFv:sFasL proteins show potent anti-tumor activity with no toxicity to normal cells.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Ideal immunotoxins are inactive until tumor binding, avoiding off-target effects.
  • Antibody fusion proteins utilizing tumor-selective death ligands (sFasL, sTRAIL) show promise.
  • Soluble FasL has limited receptor activity; sTRAIL is safe for normal cells.

Purpose of the Study:

  • To review the rationale and perspectives of scFv:TRAIL/scFv:sFasL fusion proteins for cancer therapy.
  • To evaluate the tumor-selective activity and safety profile of these novel immunotoxins.

Main Methods:

  • Development of fusion proteins combining anti-tumor antibody fragments (scFv) with sFasL or sTRAIL.
  • Assessment of the activity of soluble fusion proteins.
  • Evaluation of anti-tumor activity upon selective binding to tumor-associated antigens.
  • Testing for off-target toxicity in normal cells.

Main Results:

  • Fusion proteins (scFv:sFasL, scFv:sTRAIL) are inactive in soluble form.
  • These proteins gain potent anti-tumor activity after binding to specific tumor antigens.
  • No signs of toxicity were observed when scFv:sTRAIL bound to normal cells.

Conclusions:

  • scFv:TRAIL and scFv:sFasL fusion proteins represent a promising strategy for targeted cancer therapy.
  • These engineered immunotoxins offer a favorable safety profile due to tumor-selective activation.
  • Further research into these fusion proteins holds significant potential for advancing cancer treatment.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...